Biotest AG's Annual Meeting Approves Dividend Distribution

During the Annual General Meeting held on July 2, 2025, Biotest AG shareholders approved a dividend distribution of €0.04 per preference share for the fiscal year 2024. Representing 71.8% of the company's share capital, the resolution received an overwhelming 99.79% approval from shareholders, aligning with the management's proposals.

The meeting also saw the approval of the actions of the Executive Board and Supervisory Board members for 2024, with all agenda items passed by a substantial majority. Dr. Jörg Schüttrumpf, CEO of Biotest AG, delivered a speech available on the company's website.

Biotest AG, a specialist in biological therapeutics derived from human plasma, operates in clinical immunology, haematology, and intensive care medicine. The company, part of the Grifols Group, employs over 2,600 people worldwide.